Latest Product Development News

AnteoTech secures a significant order from the Serum Institute of India and expands its Life Sciences pipeline with new product developments and global partnerships, positioning for accelerated growth in 2026.

Unith Ltd has strengthened its financial footing by securing a $1 million unsecured facility and receiving initial R&D tax refunds from Spain, validating its advanced AI platform and supporting its growth ambitions.

Advanced Innergy Holdings Ltd (AIH) has delivered strong audited FY25 financial results, marked by solid revenue growth, improved profitability, and strategic acquisitions, while confirming FY26 guidance and debuting on the ASX.

Nutritional Growth Solutions announces the departure of CEO Stephen J. Turner, appointing Non-Executive Director Andrew Grover as interim CEO to steer the company through its next phase.

CONNEQT Health has raised $3.1 million through an institutional placement to fuel growth of its Pulse vascular health device, supported by both new and existing investors including its largest shareholder.

WRKR Limited has agreed to acquire PaidRight, a leading payroll compliance platform, in a strategic move to expand beyond superannuation compliance. The deal, valued at approximately A$11.4 million, aims to integrate advanced real-time payroll compliance technology into WRKR’s platform.

Micro-X Limited has secured $6 million through a share placement to accelerate commercialisation of its innovative medical imaging technologies, with strategic partner Billion Prima increasing its stake to 8.5%. The capital raise supports key clinical trials and product development milestones.

Zeotech Limited has completed a significant test pit at its Toondoon Kaolin Project, producing over 2,300 tonnes of kaolin and progressing key approvals to fast-track mining and product development.

Epiminder Limited has settled a $15.77 million tax liability with the ATO related to historical R&D claims, freeing up $4.23 million from IPO proceeds for working capital.

HITIQ Limited has successfully completed the initial tranche of a $900,000 placement, issuing over 40 million shares with attached options, while director participation awaits shareholder approval.

Biome Australia has initiated its first human clinical trial for the proprietary probiotic strain Lactobacillus plantarum BMB18, aiming to validate its benefits for digestive and mood-related symptoms.

Echo IQ has formally lodged its FDA 510(k) submission for EchoSolv HF, an AI-driven heart failure diagnostic software validated by Mayo Clinic data, aiming to tap into a $60 billion US market.